Endoscopic Duodenal-Jejunal Bypass Sleeve for Obesity and Metabolic Syndrome
Tests a sleeve placed in the small intestine in adults with obesity.
Plain-language title generated from the registry record
Registry title: Duodenal-jejunal Bypass Sleeve (DJBS) for Obesity and Metabolic Syndrome
Key facts
- Where
- Shatin, Hong KongSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07675122, who can take part
Where in Hong Kong
- Chinese University of Hong KongShatin, Hong KongTaking people
- CUHK Medical CentreShatin, Hong KongNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT07675122
- Record updated
- 15 September 2026
- Original description
This study is designed to evaluate the efficacy, safety, and mechanisms of duodenal-jejunal bypass sleeve in patients with obesityRead full original descriptionShow less
Endoscopic Duodenal-jejunal Bypass Sleeve for Treatment of Obesity and Metabolic Syndrome - a Multicenter Pilot Study
This study is designed to evaluate the efficacy, safety, and mechanisms of duodenal-jejunal bypass sleeve in patients with obesity
Inclusion: Body mass index (BMI) ≥27.5kg/m2; or BMI ≥25 kg/m2 with metabolic syndrome.
Exclusion: Patients who are currently taking weight loss drugs such as orlistat; Those who have taken antiplatelet drugs or anticoagulant drugs such as aspirin in the past month; Duodenal bulb ulcer, gastric ulcer or previous and existing pancreatitis; Gastrointestinal malformations, such as patients with gastrointestinal atresia or other patients who will cause gastrointestinal implantation failure; Those with a history of cholecystitis and liver abscess; There is a known infection, and the type of disease and the severity of the infection are not suitable for use by clinicians; Drug or alcohol abuse addiction or suffering from uncontrollable mental illness; Coronary heart disease, angina, cardiac function grade III or above, or pulmonary dysfunction; Patients with potential bleeding or telangiectasia in the stomach, esophagus, small intestine and other parts; Have a history of systemic lupus erythematosus, scleroderma; Those who are allergic to nickel-titanium; Severe liver and kidney dysfunction, AST /ALT > 2.5 times, total bilirubin > 35 μmol/L, blood creatinine concentration greater than 180 μmol/L; Patients who have lost more than 5 kg of weight in the past three months; Patients who have used glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the past three months; iron deficiency or iron deficiency anemia; coagulation dysfunction; Patients with ASA IV \& V; Patients who have undergone ERCP before; Those who have contraindications to endoscopy (judged by clinicians); Pregnant women or those who are preparing to become pregnant; Any other situation that the clinician deems unsuitable for participation in this product.